ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Early Tacrolimus Exposure is Associated with BK-Viremia in Kidney Transplant Recipients

S. Meziyerh, A. L. van Rijn, D. van der Helm, P. J. van der Boog, T. van Gelder, A. C. Kroes, J. W. de Fijter, D. J. Moes, J. I. Rotmans, M. C. Feltkamp, A. P. de Vries

LUMC, Leiden, Netherlands

Meeting: 2022 American Transplant Congress

Abstract number: 259

Keywords: Immunosuppression, Infection, Polyma virus, Toxocity

Topic: Clinical Science » Infection Disease » 26 - Kidney: Polyoma

Session Information

Session Name: Kidney: Polyoma Infections

Session Type: Rapid Fire Oral Abstract

Date: Monday, June 6, 2022

Session Time: 3:30pm-5:00pm

 Presentation Time: 4:40pm-4:50pm

Location: Hynes Room 309

*Purpose: There is scant evidence to what extent maintenance immunosuppression is quantitatively associated with BK viremia. We investigated the association between tacrolimus (tac) whole blood exposure and mycophenolic acid (mpa) plasma exposure with consecutive BK viremia within the first year posttransplant.

*Methods: For this retrospective cohort study, 713 kidney transplant recipients (KTRs) transplanted at our center between 2013-2018 and treated with Tac, mpa and prednisolone, were selected from the local database. Both trough levels (C0) and area-under-the-curve (AUC) measurements of tac and BK viral loads were determined according to local protocol. Exposure measurements were carried backwards to assess exposure on landmarks: month 1.5, 3 and 6. Patients with no measurement of tac or mpa exposure within the first year due to switches were excluded, leaving 508 patients for analysis. Incidence and time to BK viremia (with load > limit of detection (LOD) and load > log 4) in the first year posttransplant were outcomes of interest. Hazard ratios (HR) of exposure to tac and mpa were assessed and adjusted for confounders such as donor and recipient age and gender, number of human leukocyte antigen (HLA) mismatch, days on dialysis, induction therapy, and living or deceased donation.

*Results: In total, 83 out of 508 (16%) KTRs developed a BK viremia (>LOD) in their first year post-transplant. Tac exposure (both C0 and AUC) on day 45 was significantly associated with subsequent development of BK viremia (load > LOD & load >log 4) with respectively unadjusted and adjusted HRs of 1.08 (95% CI: 1.02-1.14) and 1.08 (95% CI: 1.01-1.15) for 1 μg/L increase in C0 and 20 mg*h/L increase in AUC0-12h. Exposure of tac on day 90 or 120 was not associated with incident BK viremia. No association between exposure to mpa and BK-viremia was identified. Moreover, HR for tac remained unchanged if adjusted for mpa exposure and other transplant characteristics.

*Conclusions: In our population, tac exposure on month 1.5 seems associated with incident BK viremia in a concentration-dependent manner. This was not found for mpa. The explanation for this finding could be that tacrolimus is a more potent suppressor of Th-lymphocytes which play a vital role in boosting viral immunity and memory. To the best of our knowledge, this is the first time that exposure to immunosuppressive drugs has been quantitatively associated with BK viremia. Future research is warranted to investigate causative and predictive impact of tac exposure on BK-incidence, which may aid physicians balance between toxicity and efficacy within the first year of transplantation.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Meziyerh S, Rijn ALvan, Helm Dvander, Gelder Tvan, Kroes AC, Fijter JWde, Moes DJ, Rotmans JI, Feltkamp MC, Vries APde. Early Tacrolimus Exposure is Associated with BK-Viremia in Kidney Transplant Recipients [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/early-tacrolimus-exposure-is-associated-with-bk-viremia-in-kidney-transplant-recipients/. Accessed May 9, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences